caa a22 4500 475785207 CHVBK 20180406123656.0 cr unu---uuuuu 170329e20000201xx s 000 0 eng 10.1007/s004310050047 doi (NATIONALLICENCE)springer-10.1007/s004310050047 Clinical course and treatment of haemorrhagic cystitis associated with BK type of human polyomavirus in nine paediatric recipients of allogeneic bone marrow transplants [Elektronische Daten] [F. Peinemann, E.-M. de Villiers, K. Dörries, O. Adams, T. A. Vögeli, S. Burdach]  Of a total of 117 bone marrow transplant (BMT) recipients in the period from August 1988 to November 1995, 9 (7.7%) developed haemorrhagic cystitis. This condition was characterized in all nine patients by late onset (day +24 to +50 post-BMT), long duration (1 to 7 weeks), and the excretion of BK virus in the urine, as confirmed by electron microscopy, DNA hybridization and PCR analysis. Adenovirus was not involved. The serological assessment of BK virus-specific IgM and IgG pre- and post-BMT is consistent with viral reactivation in all patients, although a primary infection cannot be absolutely excluded in a single patient. A significant correlation between the use of high-dose busulphan (16 mg/kg) in the preparative regimen and development of haemorrhagic cystitis (P = 0.0003) was evident. The severe course of the disease in two patients resulted in bladder tamponade; bleeding could not be inhibited with coagulation and laser treatment. Deterioration was prevented by bladder irrigation via a suprapubic catheter. Remission occurred spontaneously in all patients. Conclusion BK virus induced haemorrhagic cystitis in a paediatric bone marrow transplantation recipients is characterized by late onset, long duration, viral reactivation and correlates to high-dose busulphan. Severe bleeding could not be influenced by surgical intervention. Springer-Verlag Berlin Heidelberg, 2000 Key words Haemorrhagic cystitis nationallicence Bone marrow transplantation nationallicence BKV nationallicence Polyomavirus nationallicence Busulphan nationallicence Peinemann F. Zentrum für Kinderheilkunde, Klinik für Pädiatrische Hämatologie und Onkologie, Heinrich-Heine-Universität, Düsseldorf, Germany, DE aut de Villiers E.-M Deutsches Krebsforschungszentrum, Abteilung Tumorvirus-Charakterisierung, Heidelberg, Germany, DE aut Dörries K. Institut für Virologie und Immunologie, Julius-Maximilians-Universität, Würzburg, Germany, DE aut Adams O. Institut für Medizinische Mikrobiologie und Virologie, Heinrich-Heine-Universität, Düsseldorf, Germany, DE aut Vögeli T. A. Urologische Klinik, Heinrich-Heine-Universität, Düsseldorf, Germany, DE aut Burdach S. Zentrum für Kinderheilkunde, Klinik für Pädiatrische Hämatologie und Onkologie, Heinrich-Heine-Universität, Düsseldorf, Germany, DE aut https://doi.org/10.1007/s004310050047 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s004310050047 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Peinemann F. Zentrum für Kinderheilkunde, Klinik für Pädiatrische Hämatologie und Onkologie, Heinrich-Heine-Universität, Düsseldorf, Germany, DE aut NATIONALLICENCE 700 1- de Villiers E.-M Deutsches Krebsforschungszentrum, Abteilung Tumorvirus-Charakterisierung, Heidelberg, Germany, DE aut NATIONALLICENCE 700 1- Dörries K. Institut für Virologie und Immunologie, Julius-Maximilians-Universität, Würzburg, Germany, DE aut NATIONALLICENCE 700 1- Adams O. Institut für Medizinische Mikrobiologie und Virologie, Heinrich-Heine-Universität, Düsseldorf, Germany, DE aut NATIONALLICENCE 700 1- Vögeli T. A. Urologische Klinik, Heinrich-Heine-Universität, Düsseldorf, Germany, DE aut NATIONALLICENCE 700 1- Burdach S. Zentrum für Kinderheilkunde, Klinik für Pädiatrische Hämatologie und Onkologie, Heinrich-Heine-Universität, Düsseldorf, Germany, DE aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer